COVID-19 Therapeutics I: Clinical Evidence Studies for the Efficacy and Safety of ATR-002 in Patients with COVID-19 (MEK-I-COV)
- Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
- Total publications:0 publications
Grant number: 16LW0001
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$13,915,182.87Funder
Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)Principal Investigator
N/A
Research Location
GermanyLead Research Institution
ATRIVA Therapeutics GmbHResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified